Sara M. Tolaney

Spatial/molecular heterogeneity and treatment response in HER2+ early breast cancer: Translational analyses from the DAPHNe trial

The paper analyzes HER2+ breast cancer using multi-platform data to identify molecular predictors of response to neoadjuvant therapy and highlights intra-tumoral heterogeneity and immune exclusion mechanisms.

APOE Tumor-Associated Macrophages and CD4-DOCK4 T Cells Reveal Distinct Microenvironmental Features in HER2-Low and HER2-0 Hormone Receptor-Positive Breast Cancer

The paper identifies distinct immune and stromal features in HR+ HER2-low and HER2-0 breast cancers using molecular and multiplexed imaging.

Clinicogenomic characterization of inflammatory breast cancer

This study analyzes genomic alterations in a large IBC cohort, finding high TP53 mutation frequency and NOTCH pathway enrichment, but no major genomic differences compared to non-IBC cases.

An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer

This study identifies an estrogen receptor signaling program in HR+ breast cancer that suppresses immune responses by reducing T cell infiltration and HLA expression, suggesting therapeutic targets to enhance immunogenicity.

MAESTRO affords 'breadth and depth' for mutation testing

MAESTRO enables efficient and accurate tracking of thousands of low-frequency mutations with reduced sequencing, improving mutation testing in cancer and liquid biopsies.

Prevalence and mutational determinants of high tumor mutation burden in breast cancer

This study finds that 5% of breast cancers have high tumor mutation burden, more common in metastatic tumors, with APOBEC activity as the most common mutational process and potential benefit from PD-1 inhibitors.